There’s been a win and a loss for dermatology patients in outcomes from the July PBAC meeting which were made public last week. The Committee recommended Authority Required PBS listing of risankizumab – an anti-IL23A antibody biologic – for patients with severe chronic plaque psoriasis. However it has, for the second time, rejected dupilumab – ...
PBAC rejects dupilumab for eczema
By Mardi Chapman
30 Aug 2019